The SPDR® S&P Biotech ETF rebounded over 20% since lows in April, despite changes at the FDA that could have signaled a ...

During a live event, Christine Bestvina, MD, reviewed outcomes from the phase 3 KRYSTAL-12 and CodeBreak 200 trials in the ...

During a live event, Christine Bestvina, MD, discussed trials of KRAS inhibitors plus immunotherapy in patients with ...

Amgen Inc. (NASDAQ:AMGN) is included among the 14 Best Pharma Dividend Stocks to Buy in 2025. In 2023, the company finalized its $28 billion acquisition of Horizon Therapeutics, a smaller biotech ...

Amgen (AMGN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Amgen Inc. (NASDAQ:AMGN) is one of the high-margin pharma stocks to buy now. HSBC has lowered its price target on Amgen Inc.

Amgen Inc. (NASDAQ: AMGN) is included among the 14 Best Pharma Dividend Stocks to Buy in 2025. A pharmacist filling a prescription for a complex drug developed by the company.

In July 2025, Amgen conducted a study is to compare progression free survival (PFS) in treatment-naïve Participants with KRAS p.G12C mutated metastatic colorectal cancer (mCRC) receiving ...